Adaptimmune Therapeutics PLC - Ordinary Shares, par value GBP 0.001 per share (ADAPY)

54 filings reported holding ADAPY - Adaptimmune Therapeutics PLC - Ordinary Shares, par value GBP 0.001 per share as of Q1 2020.
Adaptimmune Therapeutics PLC - Ordinary Shares, par value GBP 0.001 per share (ADAPY) has 45 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 93,844,355 shares of 1,571,428,571 outstanding shares and own 6% of the company stock.
Largest 10 shareholders include Matrix Capital Management Company, LP (34,428,730 shares), NEA Management Company, LLC (17,082,611 shares), RA CAPITAL MANAGEMENT, L.P. (12,541,888 shares), Capital World Investors (8,002,700 shares), BAILLIE GIFFORD & CO (4,354,023 shares), BAKER BROS. ADVISORS LP (3,690,307 shares), ORBIMED ADVISORS LLC (2,525,654 shares), CITADEL ADVISORS LLC (2,053,205 shares), RENAISSANCE TECHNOLOGIES LLC (1,749,960 shares), and FMR LLC (1,578,783 shares).
This table shows the top 45 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.

* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.